MedWatch

FDA fast-tracks Abbvie's lung cancer drug

The investigational drug against non-small cell lung cancer can look forward to special treatment by the FDA, which has granted the drug Breakthrough Therapy Designation.

Photo: Abbvie / PR

Abbvie starts out 2022 with positive news, as the US Food and Drug Administration (FDA) sees big potential in Abbvie's investigational antibody-drug conjugate, telisotuzumab vedotin.

In a press release on Wednesday, Abbvie announces that the FDA has granted Breakthrough Therapy Designation to the drug, fast-tracking the case processing of the treatment against non-small cell lung cancer (NSCLC).

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs